Andrew Gengos - 16 Jul 2026 Form 4 Insider Report for Immuneering Corp (IMRX)

Reporting relationship: Chief Financial Officer
Issuer ticker: IMRX
Reported as of: 16 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jul 2026, 16:29:06 UTC
Prior SEC filing: 08 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael D. Bookman, Attorney-in-Fact for Andrew Gengos

Key filing fact

Andrew Gengos filed Form 4 for Immuneering Corp (IMRX) on 17 Jul 2026.

Key facts

This page summarizes Andrew Gengos's Form 4 filing for Immuneering Corp (IMRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Jul 2026, 16:29.

Change

Previous filing in this sequence was filed on 08 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001563623 Primary reporting owner

Gengos Andrew

Relationship: Chief Financial Officer
Address: 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Signature: /s/ Michael D. Bookman, Attorney-in-Fact for Andrew Gengos
Signature date: 17 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMRX transaction Derivative

Stock Option

Award

Transaction value
Shares: +650,000
Change %
Price: $0.000000^*
Shares after: 650,000
Date: 16 Jul 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 650,000
Exercise price: $4.78
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Subject to the reporting person's continued employment through each applicable vesting date, 8.33333% of the shares underlying the stock option shall vest on each of the first, second and third monthly anniversary of the grant transaction date (the "Grant Date"); 1.6667% of the shares underlying the stock option shall vest on the fourth monthly anniversary of the Grant Date and on each monthly anniversary thereafter until the one year anniversary of the Grant Date; 3.33333% of the shares underlying the stock option shall vest on each monthly anniversary following the one-year anniversary of the Grant Date until the second anniversary of the Grant Date; and 0.833333% of the of the shares underlying the stock option shall vest on each monthly anniversary following the second anniversary of the Grant Date until the fourth anniversary of the Grant Date, such that all shares underlying the stock option shall be fully vested on the fourth anniversary of the Grant Date.